AI summary · may contain errors
Intermittent dasatinib with a weekend holiday is noninferior to continuous 100 mg daily for major molecular remission at 24 months in first-line chronic phase chronic myeloid leukemia, with 81% vs 78%.
Moving in Leukemia, Blood, Blood Cancer Discovery, Cancer Research, Cell Research, JNCI: Journal of the National Cancer Institute, Journal of Clinical Oncology and Nature.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
Intermittent dasatinib with a weekend holiday is noninferior to continuous 100 mg daily for major molecular remission at 24 months in first-line chronic phase chronic myeloid leukemia, with 81% vs 78%.
AI summary · may contain errors
In 202 chronic myeloid leukemia patients treated with olverembatinib or ponatinib, the high-burden ASXL1 p.G646Wfs*12 variant is the most consistent genomic marker of inferior responses and outcomes.
AI summary · may contain errors
In older patients (>60) with newly diagnosed AML, adding quizartinib to intensive chemotherapy improved overall survival only for FLT3-mutated disease (HR 0.59, 95% CI 0.37–0.93).
AI summary · may contain errors
KHSRP is the top vulnerability in therapy-persistent acute myeloid leukemia, and its depletion sensitizes AML to treatment and substantially prolongs survival in treated AML-bearing mice.
AI summary · may contain errors
Relcobatinib (ELVN-001) shows marked selectivity for BCR::ABL1 and robust anti-tumor activity in a human CML mouse xenograft model as monotherapy and with asciminib.
AI summary · may contain errors
Clinically relevant chronic myeloid leukemia phenotypes emerge clearly at the pseudobulk (macrostate) level despite continuous single-cell transcriptional microstates.
AI summary · may contain errors
In pediatric acute myeloid leukemia, DHX15 R222G mutations are linked to inferior prognosis, and they cooperate with RUNX1::RUNX1T1 to sustain leukemia stem cell activity.
AI summary · may contain errors
Long-term chronic myeloid leukemia patients treated with tyrosine kinase inhibitors show worse health status than non-CML controls, with 71.0% reporting ≥1 adversely affected domain.
AI summary · may contain errors
In KMT2A-rearranged B-cell acute lymphoblastic leukemia, the ITGA4–NG2 axis is linked to Rho GTPase activity and leukemic aggressiveness, and natalizumab delays progression in xenografts.
AI summary · may contain errors
Ziftomenib 600 mg plus venetoclax/azacitidine achieved a 46% composite complete remission rate in 48 adults with relapsed/refractory NPM1-mutated acute myeloid leukemia.
AI summary · may contain errors
Platelet-biased, Vwf-positive hematopoietic stem cells initiate CALR-mutated myeloproliferative neoplasms, with CALRdel52 showing selective Vwf-positive HSC amplification linked to PERK/eIF2a signaling.
AI summary · may contain errors
Venetoclax plus pediatric-inspired chemotherapy in newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia achieved 73.0% measurable residual disease negativity after induction in 167 adolescents and adults.
AI summary · may contain errors
PonatiLink-2, a bitopic ABL1 inhibitor, maintains or surpasses ponatinib potency against resistance mutants and shows an enhanced therapeutic window in vitro and in vivo.
Journals this month
Topics moving, week to 17 Nov 2026
By field